According to Zacks, “Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. “
CYAD has been the subject of several other reports. HC Wainwright cut their price target on Celyad Oncology from $17.00 to $15.00 and set a buy rating for the company in a report on Friday, August 6th. Jonestrading reiterated a hold rating on shares of Celyad Oncology in a report on Friday, August 20th.
An institutional investor recently bought a new position in Celyad Oncology stock. Endurant Capital Management LP acquired a new position in shares of Celyad Oncology SA (NASDAQ:CYAD) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 160,691 shares of the company’s stock, valued at approximately $845,000. Endurant Capital Management LP owned about 1.04% of Celyad Oncology as of its most recent SEC filing. Institutional investors and hedge funds own 1.83% of the company’s stock.
About Celyad Oncology
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company’s Cardiopoiesis, Corquest, and C-Cathez platforms.
Read More: What is the Euro STOXX 50 Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celyad Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad Oncology and related companies with MarketBeat.com's FREE daily email newsletter.